SGLT2 inhibitors, with empagliflozin as a representative, are new drugs for treating type 2 diabetes (Zhao et al. 2023; Ferreira et al. 2022; Lu et al. 2022). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.